BR112021025383A2 - Metiltionínio para uso no tratamento de sinaptopatias - Google Patents
Metiltionínio para uso no tratamento de sinaptopatiasInfo
- Publication number
- BR112021025383A2 BR112021025383A2 BR112021025383A BR112021025383A BR112021025383A2 BR 112021025383 A2 BR112021025383 A2 BR 112021025383A2 BR 112021025383 A BR112021025383 A BR 112021025383A BR 112021025383 A BR112021025383 A BR 112021025383A BR 112021025383 A2 BR112021025383 A2 BR 112021025383A2
- Authority
- BR
- Brazil
- Prior art keywords
- synaptopathies
- methylthioninium
- treatment
- leucomethylthioninium
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1909506.6A GB201909506D0 (en) | 2019-07-02 | 2019-07-02 | Synaptopathies |
| PCT/EP2020/068306 WO2021001326A1 (en) | 2019-07-02 | 2020-06-29 | Methylthioninium for use in the treatment of synaptopathies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021025383A2 true BR112021025383A2 (pt) | 2022-02-01 |
Family
ID=67540130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021025383A BR112021025383A2 (pt) | 2019-07-02 | 2020-06-29 | Metiltionínio para uso no tratamento de sinaptopatias |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220370470A1 (enExample) |
| EP (1) | EP3993805A1 (enExample) |
| JP (1) | JP7610537B2 (enExample) |
| KR (1) | KR20220029711A (enExample) |
| CN (1) | CN114080224A (enExample) |
| AU (1) | AU2020300792B2 (enExample) |
| BR (1) | BR112021025383A2 (enExample) |
| CA (1) | CA3143787A1 (enExample) |
| GB (1) | GB201909506D0 (enExample) |
| IL (1) | IL289371A (enExample) |
| MX (1) | MX2021015288A (enExample) |
| WO (1) | WO2021001326A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY148145A (en) | 2006-07-11 | 2013-03-15 | Wista Lab Ltd | Methods of synthesis and/or purification of diaminophenothiazinium compounds |
| FI4385512T3 (fi) | 2018-07-26 | 2026-01-12 | Taurx Therapeutics Man Ltd | Diaminofenotiatsiinien optimoitu annostus populaatioille |
| WO2021211640A1 (en) * | 2020-04-14 | 2021-10-21 | University Of Florida Research Foundation, Incorporated | Enhanced effects of gene-immunotherapy and immunosuppressants in multiple sclerosis |
| US12410394B2 (en) | 2023-01-06 | 2025-09-09 | Athergen, Inc. | Composition comprising nicotinamide mononucleotide and leucomethylene blue |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020040032A1 (en) | 2000-07-07 | 2002-04-04 | Glasky Michelle S. | Methods for stimulation of synthesis of synaptophysin in the central nervous system |
| GB0100119D0 (en) | 2001-01-03 | 2001-02-14 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| ES2349322T7 (es) | 2006-03-29 | 2019-10-17 | Wista Lab Ltd | Sales de 3,7-diamino-10H-fenotiazina y su utilización |
| AU2008265045B2 (en) | 2007-06-19 | 2014-02-27 | Taurx Therapeutics Management Ltd. | Phenothiazine compounds for treating Mild Cognitive Impairment |
| CA2701075C (en) | 2007-10-03 | 2019-02-12 | Wista Laboratories Ltd. | Therapeutic use of diaminophenothiazines. |
| JP5898701B2 (ja) | 2011-02-11 | 2016-04-13 | ウィスタ ラボラトリーズ リミテッド | フェノチアジンジアミニウム塩およびそれらの使用 |
| JP7073330B2 (ja) * | 2016-07-25 | 2022-05-23 | ウィスタ ラボラトリーズ リミテッド | ジアミノフェノチアジンの投与及び投与量 |
| GB201614834D0 (en) | 2016-09-01 | 2016-10-19 | Wista Lab Ltd | Treatment of dementia |
| JP6756661B2 (ja) | 2017-04-28 | 2020-09-16 | 日立オートモティブシステムズ株式会社 | 車両電子制御装置 |
-
2019
- 2019-07-02 GB GBGB1909506.6A patent/GB201909506D0/en not_active Ceased
-
2020
- 2020-06-29 MX MX2021015288A patent/MX2021015288A/es unknown
- 2020-06-29 CN CN202080048560.8A patent/CN114080224A/zh active Pending
- 2020-06-29 CA CA3143787A patent/CA3143787A1/en active Pending
- 2020-06-29 BR BR112021025383A patent/BR112021025383A2/pt unknown
- 2020-06-29 EP EP20737381.2A patent/EP3993805A1/en active Pending
- 2020-06-29 KR KR1020227003215A patent/KR20220029711A/ko not_active Ceased
- 2020-06-29 AU AU2020300792A patent/AU2020300792B2/en active Active
- 2020-06-29 JP JP2021577316A patent/JP7610537B2/ja active Active
- 2020-06-29 US US17/620,966 patent/US20220370470A1/en not_active Abandoned
- 2020-06-29 WO PCT/EP2020/068306 patent/WO2021001326A1/en not_active Ceased
-
2021
- 2021-12-26 IL IL289371A patent/IL289371A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP7610537B2 (ja) | 2025-01-08 |
| KR20220029711A (ko) | 2022-03-08 |
| CN114080224A (zh) | 2022-02-22 |
| US20220370470A1 (en) | 2022-11-24 |
| MX2021015288A (es) | 2022-01-18 |
| CA3143787A1 (en) | 2021-01-07 |
| AU2020300792B2 (en) | 2026-03-19 |
| AU2020300792A1 (en) | 2022-02-24 |
| JP2022538286A (ja) | 2022-09-01 |
| GB201909506D0 (en) | 2019-08-14 |
| IL289371A (en) | 2022-02-01 |
| WO2021001326A1 (en) | 2021-01-07 |
| EP3993805A1 (en) | 2022-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021025383A2 (pt) | Metiltionínio para uso no tratamento de sinaptopatias | |
| BR112022007595A2 (pt) | Métodos para tratar doença de alzheimer | |
| CL2021001575A1 (es) | Pirazolopirimidinas sustituidas y purinas sustituidas y su uso como inhibidores de proteasa procesadora específica de ubiquitina 1 (usp1) | |
| MX383499B (es) | Agentes terapeuticos para enfermedades neurodegenerativas | |
| ECSP20030074A (es) | Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson | |
| BR112018012327A2 (pt) | compostos de diamina-arilsulfonamida substituídos com hidroxialquilamina e hidroxicicloalquilamina com atividade seletiva em canais de sódio ativados por voltagem | |
| BR112018070602A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio | |
| MX2017010982A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| BR112018000624A2 (pt) | compostos de indazol e azaindazol como inibidores de irak-4 | |
| BR112021022951A2 (pt) | Composições e métodos para o tratamento de doenças mediadas por atpase | |
| BR112017026535A2 (pt) | composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto | |
| BR112021018156A2 (pt) | Antagonistas de ngf para uso médico | |
| MX384429B (es) | Formulaciones de aminoácidos de liberación modificada administradas por vía oral. | |
| BR112017000520A2 (pt) | composto ou sal do mesmo, uso um composto ou de um sal, e, kit. | |
| MX2019014711A (es) | Polimeros de union a protones para administracion oral. | |
| CO2020006361A2 (es) | Tratamiento antisentido del síndrome de angelman | |
| MX2022002056A (es) | Compuestos para el tratamiento de enfermedad respiratoria bovina o porcina. | |
| BR112023015061A2 (pt) | Compostos antiparasitários | |
| CY1124640T1 (el) | Μια meθοδος αντιμετωπισης μυκητιασικων μολυνσεων | |
| SI3347002T1 (sl) | Zdravljenje Alzheimerjeve bolezni pri določeni populaciji bolnikov | |
| BR112022024195A2 (pt) | Anticorpos anti-tgfss e usos terapêuticos dos mesmos | |
| EP3922264A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION, IMPROVEMENT OR TREATMENT OF SKIN DISEASES | |
| BR112017021583A2 (pt) | métodos para o tratamento de transtornos inflamatórios | |
| BR112017019337A2 (pt) | tratamento de dor | |
| BR112019004791A2 (pt) | tratamento de esclerose múltipla com chs-131 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |